Characterization of Fluoxetine Plus Olanzapine Treatment in Rats: A Behavior, Endocrine, and Immediate-Early Gene Expression Analysis

Synapse

Volumn 50, Issue 4, 2003, Pages 353-364

  Horowitz, Judith M ^a   Goyal, Alpna ^b   Ramdeen, Navindra ^b   Hallas, Brian H ^b   Horowitz, A Thomas ^c   Torres, German ^b  

^a MEDAILLE COLLEGE   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c Ken Ton Union Free Schools   (United States)

Author keywords

Brain; Corticosterone; Depression; Feeding behavior; Motor activity; Schizophrenia

Indexed keywords

CORTICOSTERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; GLUCOSE; OLANZAPINE; PROTEIN FOS; TRANSCRIPTION FACTOR;

ANALYTIC METHOD; ANGULAR PATH ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY POSITION; BODY WEIGHT; CONTROLLED STUDY; CORTICOSTERONE RELEASE; DEPRESSION; DRUG EXPOSURE; DRUG POTENTIATION; ENDOCRINE FUNCTION; GENE EXPRESSION; GENE REPRESSION; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HORMONE DETERMINATION; IMMEDIATE EARLY GENE; IMMUNOCYTOCHEMISTRY; LOCOMOTION; MALE; MONOTHERAPY; MOTOR ACTIVITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN INDUCTION; PSYCHOPHARMACOTHERAPY; PYRIFORM CORTEX; RAT; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CORTICOSTERONE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG INTERACTIONS; FLUOXETINE; GENE EXPRESSION; GENES, IMMEDIATE-EARLY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MOVEMENT; PIRENZEPINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, LONG-EVANS; TIME FACTORS;

EID: 0242485334     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10276     Document Type: Article

References (31)

1. Barden N, Reul J, Holsboer F. 1995. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 18:6-11.
2. Barton CL, Hutson PH. 1999. Inhibition of hippocampal 5-HT synthesis by fluoxetine and peroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors. Synapse 31:13-19.
3. Bhana N, Foster RH, Olney R, Plosker GL. 2001. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61910:111-161.
4. Cools AR, Prinssen EPM, Ellenbroek BA. 1995. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 119:423-439.
5. Coyle JT, Duman RS. 2003. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38:157-160.
6. Curzon G, Gibson EL, Oluyomi AO. 1997. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 18:22-25.
7. Damjanoska KJ, Van De Kar LD, Kindel GH, Zhang Y, D'Souza DN, Garcia F, Battaglia G, Muma NA. 2003. Chronic fluoxetine differentially affects 5-hydroxytryptamine 2A receptor signaling in frontal cortex, oxytocin- and corticotrophin-releasing factor-containing neurons in rat paraventricular nucleus. J Pharmacol Exp Ther 306:563-571.
8. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. 1998. Brain corticosteroid receptor balance in health and disease. Endo Rev 19:269-301.
9. Duman RS, Malberg J, Thome J. 1999. Neural plasticity to stress and antidepressant treatment. Soc Biol Psychiatry 46:1181-1191.
10. Fadel J, Bubser M, Deutch AY. 2002. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22:6742-6746.
11. Fava M, Kendler KS. 2000. Major depressive disorder. Neuron 28: 335-341.
12. Gardier AM, Moratalla R, Cuellar B, Sacerdote M, Guibert B, Lebrec H, Graybiel AM. 2000. Interactions between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons. J Neurochem 74:1365-1371.
13. Kalivas PW, Duffy P, DuMars J, Skinner C. 1988. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther 245:484-492.
14. Kinon BJ, Basson BR, Tollefson GD. 2000. Effect of long-term olanzapine treatment on weight change in schizophrenia. Schizophr Res 41:195-196.
15. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E. 2002. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83:1043-1053.
16. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM. 2003. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increase MEK activities. Neuroscience 116:425-435.
17. Lonze BE, Ginty DD. 2002. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35:605-623.
18. Manji HK, Drevets WC, Charney DS. 2001. The cellular neurobiology of depression. Nat Med 7:541-547.
19. Morinobu S, Strausbaugh H, Terwilliger R, Duman RS. 1997. Regulation of c-Fos and NGF1-A by antidepressant treatments. Synapse 25:313-320.
20. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. 2002. Neurobiology of depression. Neuron 34:13-25.
21. Nibuya M, Nestler, EJ, Duman RS. 1996. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372.
22. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. New York: Academic Press.
23. Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Greengard P, Fisone G. 2003. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and ELK-1 phosphorylation in mouse dorsal striatum. J Neurochem 86:451-459.
24. Robertson GS, Fibiger HC. 1996. Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology 14: 105-110.
25. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. 1999. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 156:1471-1472.
26. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134.
27. Tohen M, Shelton R, Tollefson GD, Stahl S, Jacobs T, Gannon KS. 1999. Olanzapine plus fluoxetine: double-blind and open-label results in treatment-resistant major depressive disorder. 12th Eur College Neuropsychopharmacol Congress (ECNP). London, September 21-25, 1999.
28. Torres G, Rivier C, Weiss F. 1994. A ketamine mixture anesthetic inhibits neuroendocrine and behavioral consequences of cocaine administration. Brain Res 656:33-42.
29. Torres G, Horowitz JM, Laflamme N, Rivest S. 1998. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neuroscience 87:463-477.
30. Wong DT, Bymaster FP, Engleman EA. 1995. Prozac (Fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441.
31. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP. 2000. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262.